PE20171443A1 - Derivados de carboxamida - Google Patents

Derivados de carboxamida

Info

Publication number
PE20171443A1
PE20171443A1 PE2017000546A PE2017000546A PE20171443A1 PE 20171443 A1 PE20171443 A1 PE 20171443A1 PE 2017000546 A PE2017000546 A PE 2017000546A PE 2017000546 A PE2017000546 A PE 2017000546A PE 20171443 A1 PE20171443 A1 PE 20171443A1
Authority
PE
Peru
Prior art keywords
refers
carboxamide
alkyl
carboxamide derivatives
compound
Prior art date
Application number
PE2017000546A
Other languages
English (en)
Inventor
Anne-Marie D'souza
Mahbub Ahmed
Robert Alexander Pulz
Lisa Ann Rooney
Nichola Smith
Thomas Josef Troxler
Kamlesh Jagdis Bala
Andrew Brearley
James Dale
David Porter
David Andrew Sandham
Duncan Shaw
Jessica Louise Taylor
Roger John Taylor
Joe Wrigglesworth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50735903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171443(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20171443A1 publication Critical patent/PE20171443A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se refiere a un derivado de carboxamida de formula (I) o una sal farmaceuticamente aceptable del mismo, donde: R1 es alquilo (C3-C6) o cicloalquilo (C3-C6); R2 es metilo; R3 es alquilo ramificado (C6-C10), alquenilo ramificado (C6-C10), entre otros. Es un compuesto seleccionado: [N-(2-ciclohexil-1,5-dimetil-3-oxo-2,3-dihidro-1H-pirazol-4-il)-5-(4-isopropilciclohex-1-en-1-il)-4-metilisoxazol-3-carboxamida]; entre otros. Tambien se refiere a una composicion farmaceutica y una combinacion. Dicho compuesto modula la actividad del factor regulador de ubiquitinacion de Smad 1 (Smurf-1) siendo util en el tratamiento de hipertension arterial pulmonar, glaucoma, entre otros
PE2017000546A 2014-05-14 2015-05-14 Derivados de carboxamida PE20171443A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14168303 2014-05-14

Publications (1)

Publication Number Publication Date
PE20171443A1 true PE20171443A1 (es) 2017-09-29

Family

ID=50735903

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000546A PE20171443A1 (es) 2014-05-14 2015-05-14 Derivados de carboxamida

Country Status (38)

Country Link
US (6) US9403810B2 (es)
EP (1) EP3143018B1 (es)
JP (1) JP6523338B2 (es)
KR (2) KR102534033B1 (es)
CN (1) CN106661012B (es)
AP (1) AP2016009550A0 (es)
AR (1) AR100440A1 (es)
AU (1) AU2015259083B2 (es)
BR (1) BR112016026552B1 (es)
CA (1) CA2948543C (es)
CL (1) CL2016002839A1 (es)
CR (1) CR20160527A (es)
CU (1) CU24434B1 (es)
CY (1) CY1124251T1 (es)
DK (1) DK3143018T3 (es)
EA (1) EA030938B1 (es)
ES (1) ES2874882T3 (es)
HR (1) HRP20210783T1 (es)
HU (1) HUE054590T2 (es)
IL (1) IL248785B (es)
JO (1) JO3610B1 (es)
LT (1) LT3143018T (es)
MA (1) MA39983B1 (es)
MX (1) MX2016014939A (es)
MY (1) MY186598A (es)
PE (1) PE20171443A1 (es)
PH (1) PH12016502246A1 (es)
PL (1) PL3143018T3 (es)
PT (1) PT3143018T (es)
RS (1) RS61874B1 (es)
SG (1) SG11201609217UA (es)
SI (1) SI3143018T1 (es)
SV (1) SV2016005313A (es)
TN (1) TN2016000489A1 (es)
TW (2) TW201946921A (es)
UY (1) UY36124A (es)
WO (1) WO2015175796A1 (es)
ZA (1) ZA201607658B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201946921A (zh) 2014-05-14 2019-12-16 瑞士商諾華公司 甲醯胺衍生物
TW201623288A (zh) 2014-05-14 2016-07-01 諾華公司 甲醯胺衍生物
EA202091101A1 (ru) * 2017-11-01 2020-08-06 Бристол-Маерс Сквибб Компани Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора
CN108689976B (zh) * 2018-07-23 2021-12-28 陕西师范大学 5-磺基水杨酸协同二氯二茂钛催化合成4-碘代四氢吡喃衍生物的方法
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655009A1 (de) 1976-12-04 1978-06-15 Hoechst Ag Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US7354722B1 (en) 1999-06-11 2008-04-08 Signal Pharmaceuticals Modulators of Smurf and BMP/TGFβ signaling pathways
AU782355B2 (en) * 1999-06-11 2005-07-21 Hsc Research And Development Limited Partnership Antagonists of BMP and TGFbeta signalling pathways
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
GB0312368D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives
WO2005030128A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
US7291743B2 (en) 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
ATE524450T1 (de) 2007-08-02 2011-09-15 Organon Nv 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
KR101218926B1 (ko) 2007-08-22 2013-01-04 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011151361A1 (en) 2010-06-03 2011-12-08 Glaxo Group Limited Novel compounds
CN103380130B (zh) 2011-02-18 2015-06-17 埃科特莱茵药品有限公司 用作为食欲素拮抗剂的新颖的吡唑和咪唑衍生物
AU2015260905A1 (en) 2014-05-14 2016-12-01 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
TW201623288A (zh) 2014-05-14 2016-07-01 諾華公司 甲醯胺衍生物
US20170088546A1 (en) * 2014-05-14 2017-03-30 Novartis Ag Carboxamide inhibitors
TW201946921A (zh) 2014-05-14 2019-12-16 瑞士商諾華公司 甲醯胺衍生物

Also Published As

Publication number Publication date
US10195181B2 (en) 2019-02-05
CA2948543C (en) 2022-08-16
EA201692300A1 (ru) 2017-04-28
WO2015175796A1 (en) 2015-11-19
CU24434B1 (es) 2019-09-04
KR102534033B1 (ko) 2023-05-19
CL2016002839A1 (es) 2017-01-27
CA2948543A1 (en) 2015-11-19
CR20160527A (es) 2017-04-28
CU20160166A7 (es) 2017-03-03
CN106661012B (zh) 2019-12-20
ES2874882T3 (es) 2021-11-05
PL3143018T3 (pl) 2021-08-30
LT3143018T (lt) 2021-06-10
BR112016026552B1 (pt) 2023-02-14
EA030938B1 (ru) 2018-10-31
PH12016502246B1 (en) 2017-01-09
TW201623296A (zh) 2016-07-01
CY1124251T1 (el) 2022-07-22
IL248785A0 (en) 2017-01-31
AP2016009550A0 (en) 2016-11-30
US20190381011A1 (en) 2019-12-19
AR100440A1 (es) 2016-10-05
PH12016502246A1 (en) 2017-01-09
KR20170003666A (ko) 2017-01-09
MA39983A (fr) 2017-03-22
ZA201607658B (en) 2017-09-27
JP6523338B2 (ja) 2019-05-29
UY36124A (es) 2016-01-08
CN106661012A (zh) 2017-05-10
US11672782B2 (en) 2023-06-13
BR112016026552A2 (pt) 2017-08-15
US20170014388A1 (en) 2017-01-19
TW201946921A (zh) 2019-12-16
US20150329529A1 (en) 2015-11-19
JO3610B1 (ar) 2020-08-27
SI3143018T1 (sl) 2021-08-31
EP3143018B1 (en) 2021-03-10
BR112016026552A8 (pt) 2021-07-06
US20200268718A1 (en) 2020-08-27
AU2015259083A1 (en) 2016-11-24
KR20230074827A (ko) 2023-05-31
RS61874B1 (sr) 2021-06-30
MX2016014939A (es) 2017-02-28
MY186598A (en) 2021-07-29
US9403810B2 (en) 2016-08-02
HUE054590T2 (hu) 2021-09-28
NZ725918A (en) 2023-09-29
SG11201609217UA (en) 2016-12-29
SV2016005313A (es) 2018-06-12
PT3143018T (pt) 2021-06-01
US20230301970A1 (en) 2023-09-28
TN2016000489A1 (en) 2018-04-04
AU2015259083B2 (en) 2017-09-14
IL248785B (en) 2020-04-30
US20210052554A1 (en) 2021-02-25
EP3143018A1 (en) 2017-03-22
TWI714528B (zh) 2021-01-01
HRP20210783T1 (hr) 2021-06-25
MA39983B1 (fr) 2021-05-31
JP2017515853A (ja) 2017-06-15
DK3143018T3 (da) 2021-05-31

Similar Documents

Publication Publication Date Title
PE20171443A1 (es) Derivados de carboxamida
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
AR101229A1 (es) Agentes inhibidores de irak4
PE20181144A1 (es) Derivados de heteroarilo como inhibidores de parp
PE20141124A1 (es) Derivados de imidazol fusionados, utiles como inhibidores de ido
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
CY1119118T1 (el) Θεραπευτικος παραγων για τις διαταραχες της διαθεσης
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
NZ748771A (en) Pharmaceutical compositions comprising nitroxyl donors
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
UY36257A (es) “compuestos de imidazopiridazina”.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
NZ628408A (en) Ingenol derivatives in reactivation of latent hiv virus
PE20180247A1 (es) Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap)
UY33150A (es) Compuestos carboxamida y su uso como inhibidores v de calpaína
PE20141789A1 (es) Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2